Katherine E Attfield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8802392/publications.pdf

Version: 2024-02-01

14

all docs

13 1,617 11 papers citations h-index

14

docs citations

h-index g-index

14 3780
times ranked citing authors

12

#	Article	IF	CITATIONS
1	The immunology of multiple sclerosis. Nature Reviews Immunology, 2022, 22, 734-750.	22.7	96
2	Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med, 2021, 2, 296-312.e8.	4.4	43
3	A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death and Disease, 2020, 11, 303.	6.3	16
4	Structural and regulatory diversity shape HLA-C protein expression levels. Nature Communications, 2017, 8, 15924.	12.8	98
5	Resolving <i>TYK2</i> locus genotype-to-phenotype differences in autoimmunity. Science Translational Medicine, 2016, 8, 363ra149.	12.4	186
6	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	21.4	312
7	<scp>CD</scp> 8 ⁺ <scp>MAIT</scp> cells infiltrate into the <scp>CNS</scp> and alterations in their blood frequencies correlate with <scp>IL</scp> â€18 serum levels in multiple sclerosis. European Journal of Immunology, 2014, 44, 3119-3128.	2.9	137
8	TCR Transgenic Mice That Shed Light on Immune and Environmental Regulators in Multiple Sclerosis. Journal of Immunology, 2013, 190, 3015-3017.	0.8	0
9	TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature, 2012, 488, 508-511.	27.8	323
10	Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis. Immunological Reviews, 2012, 248, 10-22.	6.0	12
11	Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain, 2011, 134, 571-584.	7.6	158
12	Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells. Journal of Immunology, 2008, 180, 4615-4620.	0.8	65
13	Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood, 2008, 112, 4170-4177.	1.4	170